

Loncar Investments Selects Cancer Research Institute as Exclusive Charitable Partner in Immunotherapy Research Donation Program

Lenexa, Kan., and New York, N.Y. – December 1, 2015 – On Giving Tuesday, Loncar Investments and the [Cancer Research Institute](#) (CRI) announced that they have entered into an exclusive charitable partnership for the [Loncar Cancer Immunotherapy ETF](#) (ticker: CNCR). Loncar Investments will use royalties it receives as the exchange-traded fund’s index provider to donate regular contributions to CRI that amount to 4 basis points, or 0.04%, of CNCR’s total assets.

“Today’s breakthroughs in cancer immunotherapy have emerged from decades of basic scientific research funded by visionary benefactors, with the Cancer Research Institute at the forefront,” said Brad Loncar, CEO of Loncar Investments. “As our index supports public companies delivering these advances to patients, we want to foster that critical early research as well. There is no better way to do that than to give to an immunotherapy pioneer like CRI.”

“The Cancer Research Institute is pleased to be the recipient of Loncar Investments’ charitable giving program,” said Jill O’Donnell-Tormey, Ph.D, CEO and Director of Scientific Affairs at CRI. “Our mission is to fuel the discovery and development of immunotherapies for all forms of cancer, and we are delighted by how the fund generates awareness of the area.”

Founded in 1953, the Cancer Research Institute is the world’s only non-profit organization dedicated to harnessing immunotherapy to conquer cancer.

The partnership is a two-year agreement, with an option for renewal in 2017. Loncar Investments has guaranteed a minimum donation of at least \$20,000 per calendar year.

Media Contact:

Lauren Davis for [ISE ETF Ventures](#)
ise@gregoryfca.com
610-228-2103

About Cancer Research Institute

The Cancer Research Institute (CRI), established in 1953, is the world’s only nonprofit organization dedicated exclusively to transforming cancer patient care by advancing scientific efforts to develop new and effective immune system-based strategies to prevent, diagnose, treat, and eventually cure all cancers. Guided by a world-renowned Scientific Advisory Council that includes three Nobel laureates and 27 members of the National Academy of Sciences, CRI has invested \$311 million in support of research conducted by immunologists and tumor immunologists at the world’s leading medical centers and universities, and has contributed to many of the key scientific advances that demonstrate the potential for immunotherapy to change the face of cancer treatment. To learn more, go to www.cancerresearch.org.

About Loncar Investments: Loncar Investments, LLC, the provider of the Loncar Immunotherapy Index, is committed to making the biotechnology space more approachable to a wider range of investors. The company is principally owned by biotech investor Brad Loncar.

For more information, follow LoncarFunds on Twitter at [@LoncarFunds](https://twitter.com/LoncarFunds).

The Funds investment objectives, risks, charges and expenses must be considered carefully before investing. The summary and statutory prospectuses contain this and other important information about the investment company, and may be obtained by calling 800.617.0004 or visiting www.loncarfunds.com. Read it carefully before investing.

Investing involves risk; Principal loss is possible.

The Loncar Cancer Immunotherapy ETF is distributed by Quasar Distributors, LLC.

A basis point is a common unit of measure for interest rates and other percentages in finance. One basis point is equal to 1/100th of 1%, or 0.01% (0.0001).

The Loncar Cancer Immunotherapy Index is an index of 30 securities that have a strategic focus on the area of cancer immunotherapy, or harnessing the immune system to fight cancer. Quotes for the index can be found under the symbol "LCINDX" on the Bloomberg Professional service and other financial data providers.

One may not directly invest in an index.